(rih-TUK-sun) A monoclonal antibody used to treat certain types of B-cell non-Hodgkin lymphoma. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Rituxan binds to the protein called CD20, which is found on B-cells. Also called rituximab.
- Browse Related Terms: 3F8, A33, alemtuzumab, AMG 162, apolizumab, BB-10901, Bexxar regimen, bispecific antibody, bispecific monoclonal antibody, Campath-1H, cBR96-doxorubicin immunoconjugate, CC-49, cCLB8, CNTO 328, denosumab, edrecolomab, epitope, galiximab, gemtuzumab, gemtuzumab ozogamicin, GM2-KLH vaccine, hA20, HCD20, hu14.18-interleukin-2 fusion protein, Hu3S193, HuAFP31, HuHMFG1, HuLuc63, HuMax-CD20, IMMU-106, immunoscintigraphy, lexatumumab, M200, MDX-060, MORAb-009, muJ591, muromonab-CD3, Mylotarg, ofatumumab, oregovomab, OvaRex, pertuzumab, pM-81, Prost 30, radioimmunodiagnostics, RAV12, Rituxan, rituximab, SGN-15, synthetic retinoid, systemic radiation therapy, tositumomab and iodine I 131 tositumomab, volociximab, yttrium